Cargando…

Screening for SARS‐CoV‐2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program

BACKGROUND: Coronavirus disease 2019 (COVID‐19) convalescent plasma (CCP) collection began in two Brazilian hospitals for treatment of severe/critical patients. METHODS AND MATERIALS: Mild/moderate COVID‐19 convalescents were selected as CCP donors after reverse transcription polymerase chain reacti...

Descripción completa

Detalles Bibliográficos
Autores principales: Wendel, Silvano, Kutner, Jose Mauro, Machado, Rafael, Fontão‐Wendel, Rita, Bub, Carolina, Fachini, Roberta, Yokoyama, Ana, Candelaria, Gabriela, Sakashita, Araci, Achkar, Ruth, Hamerschlak, Nelson, Scuracchio, Patricia, Amaral, Marcelo, Dal Ben, Mirian, Araujo, Danielle, Soares, Camila, Camargo, Anamaria, Kallás, Esper, Durigon, Edison, Reis, Luiz Fernando, Rizzo, Luiz Vicente
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756544/
https://www.ncbi.nlm.nih.gov/pubmed/32935877
http://dx.doi.org/10.1111/trf.16065
_version_ 1783626566011453440
author Wendel, Silvano
Kutner, Jose Mauro
Machado, Rafael
Fontão‐Wendel, Rita
Bub, Carolina
Fachini, Roberta
Yokoyama, Ana
Candelaria, Gabriela
Sakashita, Araci
Achkar, Ruth
Hamerschlak, Nelson
Scuracchio, Patricia
Amaral, Marcelo
Dal Ben, Mirian
Araujo, Danielle
Soares, Camila
Camargo, Anamaria
Kallás, Esper
Durigon, Edison
Reis, Luiz Fernando
Rizzo, Luiz Vicente
author_facet Wendel, Silvano
Kutner, Jose Mauro
Machado, Rafael
Fontão‐Wendel, Rita
Bub, Carolina
Fachini, Roberta
Yokoyama, Ana
Candelaria, Gabriela
Sakashita, Araci
Achkar, Ruth
Hamerschlak, Nelson
Scuracchio, Patricia
Amaral, Marcelo
Dal Ben, Mirian
Araujo, Danielle
Soares, Camila
Camargo, Anamaria
Kallás, Esper
Durigon, Edison
Reis, Luiz Fernando
Rizzo, Luiz Vicente
author_sort Wendel, Silvano
collection PubMed
description BACKGROUND: Coronavirus disease 2019 (COVID‐19) convalescent plasma (CCP) collection began in two Brazilian hospitals for treatment of severe/critical patients. METHODS AND MATERIALS: Mild/moderate COVID‐19 convalescents were selected as CCP donors after reverse transcription polymerase chain reaction (RT‐PCR) confirmed severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and absence of symptoms for ≥14 days plus (a) age (18‐60 years), body weight greater than 55 kg; (b) immunohematological studies; (c) no infectious markers of hepatitis B virus, hepatitis C virus, human immunodeficiency virus, human T‐lymphotropic virus‐1/2, Chagas and syphilis infection; (d) no HLA antibodies (multiparous); (e) second RT‐PCR (nasopharyngeal swab and/or blood) negativity; (f) virus neutralization test (cytopathic effect–based virus neutralization test neutralizing antibody) and anti–nucleocapsid protein SARS‐CoV‐2 IgM, IgG, and IgA enzyme‐linked immunosorbent assays. RESULTS: Among 271 donors (41 females, 230 males), 250 presented with neutralizing antibodies. Final RT‐PCR was negative on swab (77.0%) or blood (88.4%; P = .46). Final definition of RT‐PCR was only defined at more than 28 days after full recovery in 59 of 174 (33.9%) RT‐PCR –ve, and 25/69 RT‐PCR +ve (36.2%; 13 between 35 and 48 days). Neutralizing antibody titers of 160 or greater were found in 63.6%. Correlation between IgG signal/cutoff of 5.0 or greater and neutralizing antibody of 160 or greater was 82.4%. Combination of final RT‐PCR –ve with neutralizing antibody ≥160 was 41.3% (112/271). Serial plasma collection showed decline in neutralizing antibody titers and IgA levels (P < .05), probably denoting a “golden period” for CCP collection (≤28 days after joining the program); IgA might have an important role as neutralizing antibody. Donor's weight, days between disease onset and serial plasma collection, and IgG and IgM levels are important predictors for neutralizing antibody titer. CONCLUSIONS: RT‐PCR +ve cases are still detected in 36.2% within 28 to 48 days after recovery. High anti–nucleocapsid protein IgG levels may be used as a surrogate marker to neutralizing antibody.
format Online
Article
Text
id pubmed-7756544
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-77565442020-12-28 Screening for SARS‐CoV‐2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program Wendel, Silvano Kutner, Jose Mauro Machado, Rafael Fontão‐Wendel, Rita Bub, Carolina Fachini, Roberta Yokoyama, Ana Candelaria, Gabriela Sakashita, Araci Achkar, Ruth Hamerschlak, Nelson Scuracchio, Patricia Amaral, Marcelo Dal Ben, Mirian Araujo, Danielle Soares, Camila Camargo, Anamaria Kallás, Esper Durigon, Edison Reis, Luiz Fernando Rizzo, Luiz Vicente Transfusion Donor Infectious Disease Testing BACKGROUND: Coronavirus disease 2019 (COVID‐19) convalescent plasma (CCP) collection began in two Brazilian hospitals for treatment of severe/critical patients. METHODS AND MATERIALS: Mild/moderate COVID‐19 convalescents were selected as CCP donors after reverse transcription polymerase chain reaction (RT‐PCR) confirmed severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and absence of symptoms for ≥14 days plus (a) age (18‐60 years), body weight greater than 55 kg; (b) immunohematological studies; (c) no infectious markers of hepatitis B virus, hepatitis C virus, human immunodeficiency virus, human T‐lymphotropic virus‐1/2, Chagas and syphilis infection; (d) no HLA antibodies (multiparous); (e) second RT‐PCR (nasopharyngeal swab and/or blood) negativity; (f) virus neutralization test (cytopathic effect–based virus neutralization test neutralizing antibody) and anti–nucleocapsid protein SARS‐CoV‐2 IgM, IgG, and IgA enzyme‐linked immunosorbent assays. RESULTS: Among 271 donors (41 females, 230 males), 250 presented with neutralizing antibodies. Final RT‐PCR was negative on swab (77.0%) or blood (88.4%; P = .46). Final definition of RT‐PCR was only defined at more than 28 days after full recovery in 59 of 174 (33.9%) RT‐PCR –ve, and 25/69 RT‐PCR +ve (36.2%; 13 between 35 and 48 days). Neutralizing antibody titers of 160 or greater were found in 63.6%. Correlation between IgG signal/cutoff of 5.0 or greater and neutralizing antibody of 160 or greater was 82.4%. Combination of final RT‐PCR –ve with neutralizing antibody ≥160 was 41.3% (112/271). Serial plasma collection showed decline in neutralizing antibody titers and IgA levels (P < .05), probably denoting a “golden period” for CCP collection (≤28 days after joining the program); IgA might have an important role as neutralizing antibody. Donor's weight, days between disease onset and serial plasma collection, and IgG and IgM levels are important predictors for neutralizing antibody titer. CONCLUSIONS: RT‐PCR +ve cases are still detected in 36.2% within 28 to 48 days after recovery. High anti–nucleocapsid protein IgG levels may be used as a surrogate marker to neutralizing antibody. John Wiley & Sons, Inc. 2020-09-16 2020-12 /pmc/articles/PMC7756544/ /pubmed/32935877 http://dx.doi.org/10.1111/trf.16065 Text en © 2020 The Authors. Transfusion published by Wiley Periodicals LLC. on behalf of AABB. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Donor Infectious Disease Testing
Wendel, Silvano
Kutner, Jose Mauro
Machado, Rafael
Fontão‐Wendel, Rita
Bub, Carolina
Fachini, Roberta
Yokoyama, Ana
Candelaria, Gabriela
Sakashita, Araci
Achkar, Ruth
Hamerschlak, Nelson
Scuracchio, Patricia
Amaral, Marcelo
Dal Ben, Mirian
Araujo, Danielle
Soares, Camila
Camargo, Anamaria
Kallás, Esper
Durigon, Edison
Reis, Luiz Fernando
Rizzo, Luiz Vicente
Screening for SARS‐CoV‐2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program
title Screening for SARS‐CoV‐2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program
title_full Screening for SARS‐CoV‐2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program
title_fullStr Screening for SARS‐CoV‐2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program
title_full_unstemmed Screening for SARS‐CoV‐2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program
title_short Screening for SARS‐CoV‐2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program
title_sort screening for sars‐cov‐2 antibodies in convalescent plasma in brazil: preliminary lessons from a voluntary convalescent donor program
topic Donor Infectious Disease Testing
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756544/
https://www.ncbi.nlm.nih.gov/pubmed/32935877
http://dx.doi.org/10.1111/trf.16065
work_keys_str_mv AT wendelsilvano screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram
AT kutnerjosemauro screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram
AT machadorafael screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram
AT fontaowendelrita screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram
AT bubcarolina screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram
AT fachiniroberta screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram
AT yokoyamaana screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram
AT candelariagabriela screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram
AT sakashitaaraci screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram
AT achkarruth screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram
AT hamerschlaknelson screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram
AT scuracchiopatricia screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram
AT amaralmarcelo screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram
AT dalbenmirian screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram
AT araujodanielle screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram
AT soarescamila screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram
AT camargoanamaria screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram
AT kallasesper screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram
AT durigonedison screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram
AT reisluizfernando screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram
AT rizzoluizvicente screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram